Specifically, on the basis of data of 902 inpatients treated for major depression or schizophrenia, this project analyzed irregularities in genetic diversity by means of multidimensional genotypic patterns and multilayer neural nets (“NNs”) in order to separate (1) treatment “responders” from “non-responders”; (2) “early improvers” from “late improvers”; and (3) patients with normal levels of Immunoglobulin M (IgM) from patients with chronically elevated IgM levels (indicating latent inflammation [42]). The gene discussed is CD40LG; the disease is schizophrenia.